BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12469173)

  • 1. Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues.
    Merseburger AS; Kuczyk MA; Serth J; Bokemeyer C; Young DY; Sun L; Connelly RR; McLeod DG; Mostofi FK; Srivastava SK; Stenzl A; Moul JW; Sesterhenn IA
    Oncol Rep; 2003; 10(1):223-8. PubMed ID: 12469173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
    Theodorescu D; Broder SR; Boyd JC; Mills SE; Frierson HF
    J Urol; 1997 Jul; 158(1):131-7. PubMed ID: 9186339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.
    Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Moul JW
    J Urol; 1996 Oct; 156(4):1511-6. PubMed ID: 8808919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors in prostate cancer.
    Stattin P
    Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer.
    Zellweger T; Ninck C; Mirlacher M; Annefeld M; Glass AG; Gasser TC; Mihatsch MJ; Gelmann EP; Bubendorf L
    Prostate; 2003 Apr; 55(1):20-9. PubMed ID: 12640657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
    Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity.
    Grossfeld GD; Olumi AF; Connolly JA; Chew K; Gibney J; Bhargava V; Waldman FM; Carroll PR
    J Urol; 1998 May; 159(5):1437-43. PubMed ID: 9554329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.
    Goto T; Nguyen BP; Nakano M; Ehara H; Yamamoto N; Deguchi T
    Urology; 2008 Jul; 72(1):167-71. PubMed ID: 18384856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.
    Karam JA; Lotan Y; Roehrborn CG; Ashfaq R; Karakiewicz PI; Shariat SF
    Prostate; 2007 May; 67(6):614-22. PubMed ID: 17299799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone.
    Erbersdobler A; Huhle S; Palisaar J; Graefen M; Hammerer P; Noldus J; Huland H
    Prostate Cancer Prostatic Dis; 2002; 5(4):279-84. PubMed ID: 12627212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis of oral squamous cell carcinoma: a tissue microarray study.
    Solomon MC; Carnelio S; Gudattu V
    Indian J Cancer; 2010; 47(2):166-72. PubMed ID: 20448381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2.
    Zagrodnik B; Kempf W; Seifert B; Müller B; Burg G; Urosevic M; Dummer R
    Cancer; 2003 Dec; 98(12):2708-14. PubMed ID: 14669293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy.
    Bauer JJ; Sesterhenn IA; Mostofi KF; McLeod DG; Srivastava S; Moul JW
    Clin Cancer Res; 1995 Nov; 1(11):1295-300. PubMed ID: 9815924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
    Abaza R; Diaz LK; Laskin WB; Pins MR
    J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent advances on molecular pathology of prostate carcinoma].
    Niu HL; Tao Y
    Ai Zheng; 2003 May; 22(5):552-6. PubMed ID: 12753724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens.
    Rubio J; Ramos D; López-Guerrero JA; Iborra I; Collado A; Solsona E; Almenar S; Llombart-Bosch A
    Eur Urol; 2005 Nov; 48(5):745-51. PubMed ID: 16139948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
    Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
    Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of proto-oncogene c-kit in high risk prostate cancer.
    Di Lorenzo G; Autorino R; D'Armiento FP; Mignogna C; De Laurentiis M; De Sio M; D'Armiento M; Damiano R; Vecchio G; De Placido S
    Eur J Surg Oncol; 2004 Nov; 30(9):987-92. PubMed ID: 15498646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease.
    Di Lorenzo G; De Placido S; Autorino R; De Laurentiis M; Mignogna C; D'Armiento M; Tortora G; De Rosa G; D'Armiento M; De Sio M; Bianco AR; D'Armiento FP
    Prostate Cancer Prostatic Dis; 2005; 8(1):54-9. PubMed ID: 15655565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.